证券代码：300142 证券简称：沃森生物 公告编号：2025-019 云南沃森生物技术股份有限公司 第五届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会第二十 七次会议于 2025 年 4 月 24 日在公司会议室召开，会议通知于 4 月 19 日以电子 邮件方式发出，本次会议以现场会议结合通讯表决的方式举行，应参加会议董事 11 名，实际参加会议董事 11 名。会议由董事长李云春先生主持，公司监事、部 分高级管理人员列席会议。本次会议的召集、召开符合《公司法》及《公司章程》 的规定。 二、董事会会议审议情况 1、审议通过了《关于<2025 年第一季度报告>的议案》 公司《2025 年第一季度报告》符合法律、法规、中国证监会和深圳证券交 易所的相关规定，报告内容真实、准确、完整地反映了公司 2025 年第一季度的 经营情况，不存在虚假记载、误导性陈述或者重大遗漏。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案获得通过。 本议案 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥462,257,650.83, a decrease of 22.93% compared to ¥599,753,563.65 in the same period last year[2] - The net profit attributable to shareholders was ¥2,646,248.58, down 81.27% from ¥14,127,534.12 year-on-year[2] - The basic earnings per share decreased by 80.68% to ¥0.0017 from ¥0.0088 in the same period last year[2] - Net profit for the period was a loss of CNY 19.68 million, compared to a profit of CNY 38.31 million in the previous year, indicating a significant decline[20] - Total operating revenue decreased to CNY 462.26 million from CNY 599.75 million, a decline of approximately 22.9% year-over-year[19] - Total operating costs decreased to CNY 426.65 million from CNY 462.15 million, a reduction of about 7.7% year-over-year[19] Cash Flow - The net cash flow from operating activities was -¥161,674,922.84, representing a decline of 113.87% compared to -¥75,593,431.77 in the previous year[2] - Cash inflow from operating activities totaled $461.36 million, down from $631.85 million year-over-year, reflecting a decrease of approximately 26.9%[22] - Cash outflow from operating activities increased to $623.03 million from $707.44 million, showing a reduction in cash outflow by about 12%[22] - The net cash flow from investment activities was -$69.62 million, an improvement from -$162.35 million in the previous period[22] - Cash outflow for the purchase of fixed assets and intangible assets decreased significantly to $70.45 million from $153.55 million, a reduction of approximately 54%[22] - The net cash flow from financing activities was -$27.35 million, compared to -$14.22 million in the previous period, indicating increased cash outflow[24] - The total cash and cash equivalents at the end of the period stood at $3.50 billion, down from $4.10 billion, reflecting a decrease of about 14.8%[24] - The company received $183,938.75 from financing activities, which is a new cash inflow compared to the previous period[24] - The cash flow from the disposal of fixed assets was $827,624, marking a new source of cash inflow[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥14,364,084,051.45, a decrease of 2.45% from ¥14,724,311,909.25 at the end of the previous year[2] - The company's total assets decreased to CNY 14.36 billion from CNY 14.72 billion, a drop of approximately 2.5%[18] - Total liabilities decreased to CNY 2.88 billion from CNY 3.22 billion, a reduction of about 10.6% year-over-year[18] - The total current assets decreased from CNY 7,066,828,580.51 to CNY 6,748,867,229.30, a reduction of about 4.5%[16] - The total non-current assets amounted to CNY 7.62 billion, slightly down from CNY 7.66 billion, a decrease of about 0.5%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 113,047[10] - The total number of shares held by the top 10 unrestricted shareholders amounts to 44,627,476 shares, with Liu Junhui being the largest shareholder[11] - The top 10 shareholders include major institutional investors, such as China Industrial Bank and E Fund Management, indicating strong institutional support[11] - The company has a significant number of shares under lock-up agreements, with a total of 39,938,290 shares locked due to management restrictions[14] - Liu Yun Chun holds 20,362,636 shares under lock-up, which is part of the management's 75% annual lock-up policy[13] - There are no significant changes in the shareholding structure due to the transfer of shares among the top shareholders[11] Operational Insights - The company reported a significant increase in prepayments by 91.09%, reaching ¥1,967.22 million due to increased procurement and R&D service payments[6] - Other income decreased by 72.34% to ¥671.45 million, primarily due to a reduction in government subsidies received compared to the previous year[8] - The fair value change income was ¥1,413.73 million, a 116.67% increase, attributed to the rise in stock prices of a listed company in Hong Kong[8] - The company has not reported any new product launches or technological advancements during this period[12] - The company reported a significant increase in financial expenses, with a net financial income of CNY -10.77 million compared to CNY -14.80 million in the previous year[20] - Research and development expenses decreased to CNY 66.90 million from CNY 87.02 million, a reduction of approximately 23.2% year-over-year[19] Audit and Compliance - The company has not undergone an audit for the first quarter report, which may affect investor confidence[23]

沃森生物（300142）公告，2025年第一季度营收为4.62亿元，同比下降22.93%；净利润为264.62万元， 同比下降81.27%。 ...

证券代码：300142 证券简称：沃森生物 云南沃森生物技术股份有限公司投资者关系活动记录表 编号：2025-001 投资者关系活动 类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 √ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他（ ） 活动参与单位名 称及人员姓名 线上参与公司 2024 年度业绩网上说明会的全体投资者 时间 2025 年 4 月 18 日 15:00-17:00 地点 价值在线（https://www.ir-online.cn/） 形式 网络平台线上交流 上市公司接待人 员姓名 董事长 李云春 董事、总裁 姚伟 独立董事 朱锦余 副总裁 吴云燕 财务总监 吴昌雄 董事会秘书 刘宇然 投资者关系活动 交流内容及具体 问答记录 1. 13 价肺炎球菌多糖结合疫苗在国内市场份额领先，是否有计划 进一步扩大市场份额？ 答：尊敬的投资者，您好！公司持续深耕国内市场，并不断拓展国 际市场。国内市场方面，公司采取科普宣传、学术交流、品牌营销等多 种方式拓展市场，深入挖掘以 13 价肺炎结合疫苗为代表的公司自主生 产疫苗产品的市场潜力，持续提升公司疫苗产品渗透率。国际市场方 面， ...

云南沃森生物技术股份有限公司 证券代码：300142 证券简称：沃森生物 公告编号：2025-018 本疫苗获批进入临床试验，对公司近期业绩不会产生重大影响。本疫苗后续 临床试验的进度和临床研究结果，以及审评和审批的时间和结果均具有一定的不 确定性。敬请广大投资者谨慎决策，注意投资风险。 特此公告。 云南沃森生物技术股份有限公司 关于收到20价肺炎球菌多糖结合疫苗《药物临床试验批准 通知书》的公告 由云南沃森生物技术股份有限公司（以下简称"公司"）及子公司云南疫苗 实验室有限公司、玉溪沃森生物技术有限公司共同申请临床试验的 20 价肺炎球 菌多糖结合疫苗于日前获得国家药品监督管理局签发的《药物临床试验批准通知 书》，通知书编号为：2025LP01099；注册分类：预防用生物制品。审批结论： 根据《中华人民共和国药品管理法》《中华人民共和国疫苗管理法》及有关规定， 经审查，2025 年 1 月 20 日受理的 20 价肺炎球菌多糖结合疫苗符合药品注册的 有关要求，同意开展 2 月龄（最小满 6 周龄）~5 岁儿童预防由本品所含 20 种肺 炎球菌血清型引起的感染性疾病的临床试验。药物临床试验应当自批准之日起 3 ...

近期沃森生物（300142）发布2024年年报，证券之星财报模型分析如下： 财务概况 沃森生物（300142）发布的2024年年报显示，公司整体业绩出现明显下滑。具体来看，营业总收入为 28.21亿元，同比下降31.41%；归母净利润为1.42亿元，同比下降66.1%；扣非净利润为1.08亿元，同比 下降81.1%。这些数据表明公司在过去一年中面临着较大的经营压力。 单季度表现 从单季度数据来看，第四季度的表现尤为不佳。第四季度营业总收入为6.8亿元，同比下降28.84%；归 母净利润为-1.14亿元，同比上升14.77%；扣非净利润为-1.16亿元，同比下降822.69%。这进一步反映了 公司在年末的经营困境。 主营收入构成 主要财务指标 公司主营收入主要来自自主疫苗，收入为25.42亿元，占总收入的90.10%，毛利率为79.95%。技术服务 收入为2.01亿元，占总收入的7.13%，毛利率高达90.21%。此外，中间产品和其他业务的收入分别为 6026.02万元和1785.79万元。 经营情况评述 毛利率与净利率 公司的毛利率为79.69%，同比减少了6.77个百分点；净利率为6.18%，同比减少了50 ...

2025年4月11日，国内疫苗龙头企业沃森生物（300142.SZ）交出了一份令市场哗然的成绩单：2024年营 业收入同比骤降31.41%至28.21亿元，归母净利润暴跌66.10%至1.42亿元，财务指标连续两年大幅下 滑。 营收"断崖式"下跌HPV疫苗价格战重创业绩 作为占据营收99%的支柱业务，自主疫苗产品的全线溃退成为业绩滑坡的主因。双价HPV疫苗在"惠民 项目"招标中价格大幅下调，叠加九价HPV疫苗扩龄竞争加剧，导致核心产品销售收入锐减。 值得警惕的是，公司资产周转率已降至0.19次的历史低点，应收账款周转率降至1.02次，暴露出产品滞 销与回款能力恶化的双重危机。尽管通过强力催收使应收账款减少6.91亿元，但经营活动现金流仍同比 下降8.58%，显示造血能力持续弱化。 反常费用结构暴露管理隐疾 在营收规模收缩的背景下，沃森生物的管理费用逆势飙升41.64%至4.22亿元，吞噬了本已微薄的利润空 间。财报披露，6800万元HPV疫苗原料及库存商品销毁、3000万元新冠疫苗存货报废，以及1866万元人 员优化费用，折射出市场预判失误与业务调整阵痛。 与之形成反差的是，研发费用连续两年收缩，2024年研 ...

目前，公司自主研发并生产上市的疫苗产品已达 8 个品种共 14 个品规，涵盖肺炎疫苗系列、脑膜炎疫苗系列、HPV 疫苗、Hib 疫苗和百白破疫苗，全面覆盖 6 周龄以上全年龄段人群。 近日，沃森生物发布2024年财报。披露公司去年营收减少31.41%至28.21亿元，归属净利下滑66.10%至1.42亿元。 报告期内，公司销售回款保持良好，同时，公司存货销毁及计提资产减值准备，以及公司持有的金融资产公允价值下 降等原因导致净利润下降。 2024 年，公司产品首次进入阿富汗、布基纳法索市场，13 价肺炎结合疫苗首次出口印度尼西亚、菲律宾和印度，23 价肺炎疫苗首次出口菲律宾。同时，公司继续向摩洛哥出口 13 价肺炎结合疫苗，并连续 7 年稳定向埃及客户交付 A 群 C 群脑膜炎球菌多糖疫苗用于其国家扩大免疫规划（EPI）。截至目前，公司产品已累计出口至 22 个国家，覆盖东 南亚、南亚、中亚、非洲、美洲等区域市场。 在海外本地化合作方面，报告期内，公司持续推进 13 价肺炎结合疫苗原液在印度尼西亚进行本地化生产技术合作， 目前已与印度尼西亚合作方之间完成了技术转移，本地化建设也已完成，将有效促进当地疫苗产业升级 ...

Core Viewpoint - Watson Bio achieved a revenue of 2.821 billion yuan and a net profit of 142 million yuan in 2024, despite a challenging vaccine industry environment [1] Group 1: Financial Performance - The company reported a revenue of 2.821 billion yuan for 2024, with a net profit of 142 million yuan [1] - The overseas business generated a revenue of 570 million yuan, showing a year-on-year growth of approximately 98% [1] - The compound annual growth rate (CAGR) of Watson Bio's overseas business over the past three years reached 105% [1] Group 2: Product Development and Market Position - Watson Bio's subsidiary, Shanghai Zerun Biotechnology Co., successfully developed a bivalent HPV vaccine that passed WHO pre-certification, gaining procurement qualifications from UNICEF and other UN agencies [1] - The company’s main product, the 13-valent pneumococcal polysaccharide conjugate vaccine, continues to hold the largest market share in the domestic market [1] - The focus is on innovative heavy-duty products, aligning with the industry's trend towards leading products [2]

Core Viewpoint - The company is a leading biopharmaceutical enterprise in China, specializing in the research, development, production, and sales of human vaccines, with a mission to create accessible and high-quality innovative vaccine products for global health [2][3]. Company Overview - The company has developed a comprehensive portfolio of vaccines, including the 13-valent pneumococcal conjugate vaccine and the HPV vaccine, maintaining a leading market share in China since their launch [3][4]. - The company has exported its vaccine products to 22 countries and regions, contributing significantly to public health both domestically and internationally [2]. Product Sales - In 2024, the company achieved sales revenue of 2.54 billion yuan from its self-developed vaccines, accounting for 90.10% of total revenue, despite increasing competition in the global vaccine market [7]. - The 13-valent pneumococcal conjugate vaccine continues to hold the top market share in China, while the dual-valent HPV vaccine focuses on government procurement projects to enhance accessibility for young girls [7]. Product Production and Approval - The company successfully produced and approved 24,639,153 doses of its vaccines in 2024, ensuring a stable market supply while balancing inventory and sales [8]. New Product Development and Registration - The company invested 24.82% of its revenue in R&D in 2024, focusing on innovative vaccine development through collaboration with academic institutions and research organizations [9]. - The company is advancing several vaccine candidates, including the mRNA vaccine for COVID-19 variants, which has completed necessary clinical trials and is in the process of registration [10][11]. Export and International Cooperation - The company achieved overseas business revenue of 570 million yuan in 2024, marking a 98% year-on-year increase, with significant exports to new markets such as Afghanistan and Burkina Faso [12]. - The company’s dual-valent HPV vaccine received WHO prequalification, enhancing its procurement eligibility for international organizations [13]. Industrialization and Management Improvement - The company completed the construction of its production expansion project and implemented a digital management system for its entire product line, enhancing operational efficiency [16]. - The company is optimizing its governance structure and internal controls to support sustainable development and risk management [18][19]. Financial Data and Shareholder Information - The company has completed share buybacks and capital reductions, enhancing shareholder returns without significantly impacting its operational capabilities [30][27].